BACKGROUND: Renal cell carcinoma (RCC) is the sixth leading cause of death in
developed countries. A third of all RCC patients are confronted with metastatic disease …

Conclusion Whatever the modest progress made for a small number of patients with MRCC,
the majority of patients will die within 5 years of diagnosis of MRCC. Therefore, there is a …

New Perspectives on the Treatment of Metastatic Renal Cell Carcinoma: An Introduction and
Historical Overview | The Oncologist | Oxford Academic Skip to Main Content Advertisement …

Metastatic renal cell carcinoma (RCC) has a poor overall survival. Localized RCC remains a
surgical disease. About 20%-30% patients who present with limited disease at the time of …

Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell
Carcinoma Page 1 Prognostic Factors for Survival in Previously Treated Patients With …

Guidelines on the management of metastatic renal cell carcinoma (RCC) have emerged
over the last couple of years because of the introduction of effective new targeted therapies …

Renal cell carcinoma is the 14th most common cancer worldwide. It is a heterogeneous
group of histopathological entities, of which the most common is clear cell renal cell …

Targeted therapies have improved survival in patients with metastatic renal cell cancer
(RCC); however, expert opinion on the optimal therapeutic strategy is divided. This …

Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …

Objective: Metastatic renal cell cancer (RCC) portends a bad prognosis, but survival is quite
different among different patients. The objective of this study was to determine prognostic …